Neuromuscular blocking agents for acute respiratory distress syndrome.
Acute Disease
Adult
Critical Care
Critical Illness
Drug Administration Schedule
Epidemiologic Methods
Female
Humans
Male
Neuromuscular Blocking Agents
/ adverse effects
Oxygen
/ blood
Partial Pressure
Prospective Studies
Respiration, Artificial
/ statistics & numerical data
Respiratory Distress Syndrome
/ drug therapy
Risk Factors
Treatment Outcome
Journal
Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
11
06
2018
revised:
22
10
2018
accepted:
25
10
2018
pubmed:
7
11
2018
medline:
18
2
2020
entrez:
7
11
2018
Statut:
ppublish
Résumé
Acute respiratory distress syndrome (ARDS) is an acute inflammatory process that impairs the ability of the lungs to oxygenate thereby resulting in respiratory failure. Treatment of ARDS is often a multimodal approach using both nonpharmacologic and pharmacologic treatment strategies in addition to trying to reverse the underlying cause of ARDS. Neuromuscular blocking agents (NMBAs) have been prescribed to patients with ARDS as they are thought to decrease inflammation, oxygen consumption, and cardiac output and help facilitate ventilator synchrony. NMBAs have only been evaluated in patients with early, severe ARDS in three multicenter, randomized, controlled trials (n = 432), but have resulted in decreased inflammation and improved oxygenation, ventilator-free days, and mortality. Despite reports of NMBAs being associated with adverse effects like postparalytic quadriparesis, myopathy, and prolonged recovery, these effects have not been seen in patients receiving short courses of NMBAs for ARDS. A large multicenter, prospective, randomized, placebo-controlled trial is ongoing to confirm benefit of NMBAs in early, severe ARDS when adjusting for limitations of the previous studies. The current available literature suggests that 48 h of NMBA therapy in patients with early, severe ARDS improves mortality, without resulting in additional patient harm.
Identifiants
pubmed: 30396789
pii: S0883-9441(18)30826-8
doi: 10.1016/j.jcrc.2018.10.019
pmc: PMC10014082
pii:
doi:
Substances chimiques
Neuromuscular Blocking Agents
0
Oxygen
S88TT14065
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-184Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
J Crit Care. 2017 Apr;38:278-283
pubmed: 28012426
Crit Care Med. 1990 Jan;18(1):103-13
pubmed: 2403503
Crit Care Med. 2006 Nov;34(11):2749-57
pubmed: 16932229
Br J Anaesth. 1956 Oct;28(10):470-80
pubmed: 13364109
Crit Care Med. 2013 May;41(5):1332-44
pubmed: 23591211
Pain. 1989 Jun;37(3):315-316
pubmed: 2569177
Ann Intensive Care. 2012 Oct 12;2(1):43
pubmed: 23062076
JAMA. 1998 Jul 8;280(2):159-65
pubmed: 9669790
J Intensive Care Med. 2003 May-Jun;18(3):139-45
pubmed: 14984632
Crit Care. 2010;14(3):R119
pubmed: 20565863
Crit Care Med. 2008 Dec;36(12):3151-5
pubmed: 18936706
Respir Care. 2017 Jul;62(7):947-952
pubmed: 28351905
Clin Chest Med. 2018 Sep;39(3):483-492
pubmed: 30122173
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Crit Care Med. 2010 Mar;38(3):779-87
pubmed: 20048676
Ann Am Thorac Soc. 2017 Jan;14(1):124-133
pubmed: 27779896
Curr Opin Crit Care. 2016 Feb;22(1):1-6
pubmed: 26645551
Intensive Care Med. 2006 Mar;32(3):391-7
pubmed: 16450097
Am J Respir Crit Care Med. 1997 Nov;156(5):1556-61
pubmed: 9372675
Am J Respir Crit Care Med. 2018 Apr 1;197(7):897-904
pubmed: 29241014
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
Rapid Commun Mass Spectrom. 1995;9(14):1457-64
pubmed: 8534894
J Thromb Haemost. 2010 Jan;8(1):121-8
pubmed: 19874469
N Engl J Med. 2010 Sep 16;363(12):1176-80
pubmed: 20843254
Intensive Care Med. 2002 Dec;28(12):1735-41
pubmed: 12447516
Chest. 2004 Oct;126(4):1267-73
pubmed: 15486392
Am J Health Syst Pharm. 2001 Dec 1;58(23):2287-99
pubmed: 11763807
Eur J Anaesthesiol. 2002 Jul;19(7):466-73
pubmed: 12113608
Am J Crit Care. 1999 Jan;8(1):490-8
pubmed: 9987547
Crit Care Med. 2016 Nov;44(11):2079-2103
pubmed: 27755068
Acta Anaesthesiol Scand Suppl. 1995;106:91-3
pubmed: 8533554
Curr Opin Crit Care. 2012 Oct;18(5):495-502
pubmed: 22941207
Pharmacotherapy. 1998 Mar-Apr;18(2):358-63
pubmed: 9545155
Ann Intern Med. 2004 Sep 21;141(6):440-5
pubmed: 15381517
Br J Anaesth. 1995 Nov;75(5):588-92
pubmed: 7577286
Am Rev Respir Dis. 1993 Jan;147(1):234-6
pubmed: 8420423
Crit Care Med. 2009 Dec;37(12):3047-53
pubmed: 19770751
Am J Crit Care. 2006 Jan;15(1):86-94; quiz 95
pubmed: 16391318
Am J Respir Crit Care Med. 2013 Apr 1;187(7):761-7
pubmed: 23370917
Lancet Neurol. 2011 Oct;10(10):931-41
pubmed: 21939902
Clin Chest Med. 2014 Dec;35(4):753-63
pubmed: 25453423
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24
pubmed: 7509706
Crit Care Med. 2004 Jan;32(1):113-9
pubmed: 14707568
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
Chest. 2007 Apr;131(4):954-63
pubmed: 17426195
Chest. 1991 Jan;99(1):176-84
pubmed: 1845860
Ann Am Thorac Soc. 2016 Jul;13(7):1105-14
pubmed: 27128143
Am J Respir Crit Care Med. 2017 May 1;195(9):1253-1263
pubmed: 28459336
Crit Care Med. 2008 Apr;36(4):1083-8
pubmed: 18401254
Minerva Anestesiol. 2015 May;81(5):567-88
pubmed: 24937499
Ann Intensive Care. 2017 Dec;7(1):79
pubmed: 28770545
N Engl J Med. 2010 Sep 16;363(12):1107-16
pubmed: 20843245
Intensive Care Med. 2015 Dec;41(12):2201-3
pubmed: 26399892
Curr Opin Crit Care. 2005 Apr;11(2):126-32
pubmed: 15758592
Crit Care Med. 1997 Apr;25(4):575-83
pubmed: 9142020
Intensive Care Med. 2017 Mar;43(3):408-418
pubmed: 28013329